Seaport Therapeutics
PublicSeaport Therapeutics is now publicly traded
The data on this page reflects Seaport Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Apr 10, 2026
Last Round
Grant
Mar 3, 2026
Total Funding Raised
$440M
Company Overview
Seaport Therapeutics is a clinical-stage biopharmaceutical company that develops innovative neuropsychiatric medicines using its proprietary Glyph technology platform to enhance oral bioavailability and reduce side effects.
Sector
Biotech
Verticals
HealthTech
AI Layer
Non-AI
Keywords
Seaport Therapeutics Comparables
Compare Seaport Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Neumora | 76% | |
| Supernus Pharmaceuticals Inc | 76% | |
| Alto Neuroscience | 73% |
For institutional investors. Book with your work email.
Seaport Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Apr 10, 2026 | ||||
| Grant | Mar 3, 2026 | ||||
| Series B | Oct 21, 2024 | ||||
| Series A | Apr 9, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Seaport Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CPP Investments | Series B |
| Invus Opportunities | Series B |
| ARCH Venture Partners | Series B, Series A |
| Foresite Capital | Series B |
| T. Rowe Price | Series B |
| ARPA-H | Grant |
| PureTech Health | Series B, Series A |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 11, 2026
Seaport Therapeutics, Inc. presents additional pharmacokinetic data at the 39th European College of Neuropsychopharmacology (ECNP) Congress
- attends_eventOct 11, 2026
Seaport Therapeutics, Inc. presents additional pharmacokinetic data from a Phase 1 trial of GlyphAgo at the 39th European College of Neuropsychopharmacology Congress, without establishing clinical benefit.
- is_developingOct 7, 2026
Seaport Therapeutics, Inc. is developing oral versions of treatments for major depressive disorder and generalised anxiety disorder using its Glyph drug-delivery platform.
- receives_financingSep 22, 2026
Seaport Therapeutics, Inc. receives $260M in gross proceeds from a Nasdaq initial public offering in May '26, following private financings completed in 2024.
- is_developingSep 9, 2026
Seaport Therapeutics, Inc. is developing GlyphAllo as a potential treatment for major depressive disorder and plans to submit positive Phase 1 driving-simulation results to the US Food & Drug Administration as part of its ongoing development program.
For institutional investors. Book with your work email.
Seaport Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.